Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

  • Professor of Medicine, Pharmacology and Toxicology, Biochemistry and Molecular Biology
  • Deputy Director, James Graham Brown Cancer Center
  • Medical Director, Clinical Trials Office, James Graham Brown Cancer Center
  • Associate Director, Translational Research Program, James Graham Brown Cancer Center
James Graham Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202

502-852-2522 - Academic Office
502-562-4370 - Patient Appointments


Clinical Expertise
Metastatic Melanoma; Refractory Solid Tumors; Clinical Trial Testing of Immunotherapeutics; Development of Anti-Metabolites as Targeted Chemotherapies

 

Education and Training

  • Medical School: University of Minnesota
  • Residency: Memorial Sloan-Kettering Cancer Center
  • Fellowship: Cornell University Medical College

 

Recent Publications

        • Liu Y, Lu X, Huang L, Wang W, Jiang G, Dean KC, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Darling DS, Postigo A, Dean DC. Erratum: Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nat Commun. 2015 Mar 19;6:6699. doi: 10.1038/ncomms7699. PubMed PMID: 25789446.
        • Stathem M, Marimuthu S, O'Neal J, Rathmell JC, Chesney JA, Beverly LJ, Siskind LJ. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. J Cell Biochem. 2015 Jan;116(1):67-80. doi: 10.1002/jcb.24943. PubMed PMID: 25145677; PubMed Central PMCID: PMC4229434.
        • Liu Y, Lu X, Huang L, Wang W, Jiang G, Dean KC, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Darling DS, Postigo A, Dean DC. Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nat Commun. 2014 Dec 1;5:5660. doi: 10.1038/ncomms6660. PubMed PMID: 25434817.
        • Chesney J, Clark J, Klarer AC, Imbert-Fernandez Y, Lane AN, Telang S. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget. 2014 Aug 30;5(16):6670-86. PubMed PMID: 25115398; PubMed Central PMCID: PMC4196155.
        • Imbert-Fernandez Y, Clem BF, O'Neal J, Kerr DA, Spaulding R, Lanceta L, Clem AL, Telang S, Chesney J. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J Biol Chem. 2014 Mar 28;289(13):9440-8. doi: 10.1074/jbc.M113.529990. Epub 2014 Feb 10. PubMed PMID: 24515104; PubMed Central PMCID: PMC3979387.
        • Liu Y, Sánchez-Tilló E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. J Biol Chem. 2014 Feb 14;289(7):4116-25. doi: 10.1074/jbc.M113.533505. Epub 2013 Dec 26. PubMed PMID: 24371144; PubMed Central PMCID: PMC3924277.
        • Klarer AC, O'Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J, Telang S. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab. 2014 Jan 23;2(1):2. doi: 10.1186/2049-3002-2-2. PubMed PMID: 24451478; PubMed Central PMCID: PMC3913946.
        • Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, Bifari F, Wang X, Blanco R, Tembuyser B, Cornelissen I, Bouché A, Vinckier S, Diaz-Moralli S, Gerhardt H, Telang S, Cascante M, Chesney J, Dewerchin M, Carmeliet P. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014 Jan 7;19(1):37-48. doi: 10.1016/j.cmet.2013.11.008. Epub 2013 Dec 12. PubMed PMID: 24332967.
        • De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembuyser B, Brepoels K, Welti J, Geudens I, Segura I, Cruys B, Bifari F, Decimo I, Blanco R, Wyns S, Vangindertael J, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hofkens J, Fraisl P, Telang S, Deberardinis RJ, Schoonjans L, Vinckier S, Chesney J, Gerhardt H, Dewerchin M, Carmeliet P. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013 Aug 1;154(3):651-63. doi: 10.1016/j.cell.2013.06.037. PubMed PMID: 23911327.
        • Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14. PubMed PMID: 23674815; PubMed Central PMCID: PMC3742633.